Antimicrobial resistance
This article was originally published in The Rose Sheet
Executive Summary
FDA, CDC and NIH will host public meeting Sept. 26 in San Diego, Calif. to solicit comments on development of Public Health Action Plan to Combat Antimicrobial Resistance. Discussion will center on second part of the action plan (global issues). Agencies held a meeting in June to discuss surveillance, prevention and control, research and product development. Evaluation of benefits and risks of antimicrobials in consumer products such as soap were included in action plan unveiled by HHS in 2001 (1"The Rose Sheet" Jan. 22, 2001, In Brief)...
You may also be interested in...
Antimicrobial action plan
Evaluation of benefits/risks of incorporating antimicrobial disinfectants or chemicals into consumer products such as soap included in final interdepartmental antimicrobial resistance action plan unveiled by HHS Jan. 18. Although not specified in the final version, a draft released in June said agencies likely will consider whether such products "have any efficacy in reducing infection" and if they "play a role in promoting drug resistance" (1"The Rose Sheet" June 26, 2000, p. 8). Developed by the Task Force on Antimicrobial Resistance, the plan designates priorities, identifies responsible agencies and creates timelines for facilitating surveillance, prevention and control, research and product development to address antimicrobial resistance. CDC, NIH and FDA are leading task force of 10 agencies and departments
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.